Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Amended) A compound of formula (I):

$$(R)p$$
 $(C)n$
 $(R^1)q$
 (I)

wherein:

n is 0,1, or 2;

X is NH, or O_{τ} or $S(O)_{m}$;

each R is the same or different and is independently selected from the group consisting

of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}\text{cycloalkyl}, \text{ Ay, -NHR}^{10}\text{Ay, Het, -NHHet, -NHR}^{10}\text{Het, -OR}^2, \text{ -OAy, -OHet, -R}^{10}\text{OR}^2, \text{ -NR}^2\text{R}^3, \text{ -NR}^2\text{Ay, -R}^{10}\text{NR}^2\text{R}^3, \text{ -R}^{10}\text{NR}^2\text{Ay, -R}^{10}\text{C}(\text{O})\text{R}^2, \text{ -C}(\text{O})\text{R}^2, \text{ -C}(\text{O})\text{R}^2, \text{ -C}(\text{O})\text{NR}^2\text{R}^3, \text{ -C}(\text{O})\text{Ay, -C}(\text{O})\text{NR}^2\text{Ay, -C}(\text{O})\text{Het, -C}^{10}\text{C}(\text{O})\text{NR}^2\text{R}^3, \text{ -C}(\text{S})\text{NR}^2\text{R}^3, \text{ -R}^{10}\text{C}(\text{S})\text{NR}^2\text{R}^3, \text{ -R}^{10}\text{NHC}(\text{NH})\text{NR}^2\text{R}^3, \text{ -C}(\text{NH})\text{NR}^2\text{R}^3, \text{ -R}^{10}\text{C}(\text{NH})\text{NR}^2\text{R}^3, \text{ -S}(\text{O})_2\text{NR}^2\text{R}^3, \text{ -S}(\text{O})_2\text{NR}^2\text{R}^3, \text{ -S}(\text{O})_2\text{NR}^2\text{R}^3, \text{ -S}(\text{O})_2\text{NR}^2, \text{ cyano, nitro, or azido;}$

each R¹ is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl, cycloalkyl, -R¹⁰cycloalkyl, Ay, -NHR¹⁰Ay, Het, -NHHet, -NHR¹⁰Het, -OR², -OAy, -OHet, -R¹⁰OR², -NR²R³, -NR²Ay, -R¹⁰NR²R³, -R¹⁰NR²Ay, -

Attorney Docket no. PR60251USW Application no. 10/560,013

$$\begin{split} R^{10}C(O)R^2, -C(O)R^2, -CO_2R^2, -R^{10}CO_2R^2, -C(O)NR^2R^3, -C(O)Ay, -C(O)NR^2Ay, -C(O)Het, -C(O)NHR^{10}Het, -R^{10}C(O)NR^2R^3, -C(S)NR^2R^3, -C(S)NR^2R^3, -R^{10}NHC(NH)NR^2R^3, -C(NH)NR^2R^3, -R^{10}C(NH)NR^2R^3, -C(NH)NR^2R^3, -R^{10}C(NH)NR^2R^3, -S(O)_2NR^2Ay, -R^{10}SO_2NHCOR^2, -R^{10}SO_2NR^2R^3, -R^{10}SO_2R^2, -S(O)_mR^2, cyano, nitro, or azido; \end{split}$$

each m independently is 0, 1, or 2;

each R¹⁰ is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5;

each of R² and R³ are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R¹⁰cycloalkyl, -R¹⁰OH, -R¹⁰(OR¹⁰)_w, and -R¹⁰NR⁴R⁵;

w is 1-10;

each of R⁴ and R⁵ are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay represents an aryl group;

Het represents a 5- or 6-membered heterocyclyl or heteroaryl group; ring A is aryl or heteroaryl; and or a pharmaceutically acceptable salt or solvate salts, solvates, and physiologically functional derivatives thereof.

- (Original) The compound of claim 1 wherein X is NH.
- 3. (Original) The compound of claim 1 wherein alkyl is C_1 - C_6 alkyl, alkoxy is C_1 - C_6 alkoxy, and haloalkyl is C_1 - C_6 haloalkyl.
- 4. (Original) The compound of claim 1 wherein at least p or q is not 0.
- 5. (Original) The compound of claim 1 wherein both p and q are each 1.
- 6. (Original) The compound of claim 1 wherein n is 1 or 2.

- 7. (Original) The compound of claim 6 wherein n is 1.
- 8. (Original) The compound of claim 1 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, -R¹⁰cycloalkyl, Ay, Het, -OR², -R¹⁰OR², -NR²R³, -COR², -CO₂R², -CONR²R³, -S(O)₂NR²R³, cyano, nitro, or azido.
- 9. (Original) The compound of claim 8 wherein R is selected from halogen, alkyl, haloalkyl, cycloalkyl, -R¹⁰cycloalkyl, Ay, Het, -R¹⁰OR², -NR²R³, -COR², -CONR²R³, -S(O)₂NR²R³, or cyano.
- 10. (Original) The compound of claim 9 wherein R is selected from halogen, alkyl, or haloalkyl.
- 11. (Original) The compound of claim 10 wherein R is selected from Cl or Br.
- 12. (Previously presented) The compound of claim 10 wherein R is substituted *para* to the depicted N atom.
- 13. (Original) The compound of claim 1 wherein R^1 selected from halogen, alkyl, haloalkyl, Ay, Het, $-OR^2$, $-R^{10}OR^2$, $-NR^2R^3$, $-COR^2$, $-CO_2R^2$, $-CONR^2R^3$, $-S(O)_2NR^2R^3$, $-S(O)_mR^2$, cyano, nitro, or azido.
- 14. (Original) The compound of claim 13 wherein R¹ is selected from halogen, alkyl, haloalkyl, -OR², cyano, or nitro.
- 15. (Currently amended) The compouns compound of claim 14 wherein R¹ is selected from halogen, alkyl, haloalkyl, -OR².

- 16. (Original) The compound of claim 15 wherein q is 1 or 2.
- 17. (Original) The compound of claim 1 wherein the A ring is aryl.
- 18. (Original) The compound of claim 17 wherein the A ring is phenyl.
- 19. (Original) The compound of claim 1 wherein the A ring is heteroaryl.
- 20. (Original) The compound of claim 19 wherein the heteroaryl is pyrimidinyl, pyridyl, or benzothiazolyl.
- 21. (Original) The compound of claim 20 wherein the heteroaryl is pyrimidinyl or pyridyl.
- 22. (Original) The compound of claim 21 wherein q is 0, 1, or 2.
- 23. (Original) The compound of claim 1 wherein when p is not 0, then each R is the same or different and is independently selected from the group consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R¹0cycloalkyl, Ay, -NHR¹0Ay, Het, -NHHet, -NHR¹0Het, -R¹0OR², -NR²R³, -NR²Ay, -R¹0NR²R³, -R¹0NR²Ay, -R¹0C(O)R², -C(O)R², -CO₂R², -R¹0CO₂R², -C(O)NR²R³, -C(O)Ay, -C(O)NR²Ay, -C(O)Het, -C(O)NHR¹0Het, -R¹0C(O)NR²R³, -C(S)NR²R³, -R¹0C(S)NR²R³, -R¹0NHC(NH)NR²R³, -C(NH)NR²R³, -R¹0C(NH)NR²R³, -R¹0C(NH)NR²R³, -S(O)₂NR²R³, -S(O)₂NR²Ay, -R¹0SO₂NHCOR², -R¹0SO₂NR²R³, -R¹0SO₂R², -S(O)_mR², cyano, nitro, or azido.
- 24. (Original) The compound of claim 1 selected from 6-Bromo-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine 6-Chloro-*N*-(4-chlorophenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

- 6-Chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
- 6-Chloro-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-*N*-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-*N*-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-N-(5-propylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Methoxy-*N*-pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Methoxy-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- *N*-(4,6-Dimethoxypyrimidin-2-yl)-6-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-[5-(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-*N*-[5-(trifluoromethyl) □ yridine-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-[(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile
- N-(1,3-Benzothiazol-2-yl)-6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- *N*-Pyrimidin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 2-Bromo-N-pyrimidin-2-yl-5,6,7,8,9,10-hexahydrocyclohepta[b]indol-6-amine
- 6-Methyl-N-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride salt
- Methyl 1-anilino-2,3,4,9-tetrahydro-1*H*-carbazole-6-carboxylate
- 6-[(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile hydrochloride salt
- N-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride

- *N*-Phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(1H-indol-5-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine; and
- 6-Bromo-*N*-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1*H*-carbazole.
- 25. (Currently amended) The compound of claim 1 selected from
- 6-Bromo-N-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-*N*-phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-*N*-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine
- 6-Chloro-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4-methylphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-(4-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
- 6-Chloro-N-pyrimidin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethoxypyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Chloro-N-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- 6-Bromo-N-pyridin-2-yl-2,3,4,9-tetrahydro-1H-carbazol-1-amine hydrochloride
- 6-Bromo-N-(5-propylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine
- *N*-(4,6-Dimethoxypyrimidin-2-yl)-6-methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride
- 6-Bromo-*N*-(4,6-dimethylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride

Attorney Docket no. PR60251USW Application no. 10/560,013

6-Bromo-*N*-[5-(trifluoromethyl)pyrimidin-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

6-Bromo-*N*-[5-(trifluoromethyl) <u>yridine</u> <u>pyridine</u>-2-yl]-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

6-[(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile *N*-(1,3-Benzothiazol-2-yl)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

2-Bromo-*N*-pyrimidin-2-yl-5,6,7,8,9,10-hexahydrocyclohepta[*b*]indol-6-amine

6-Methyl-*N*-pyridin-2-yl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride salt

Methyl 1-anilino-2,3,4,9-tetrahydro-1*H*-carbazole-6-carboxylate

6-[(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)amino]nicotinonitrile

hydrochloride salt

N-Phenyl-6-(trifluoromethyl)-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine hydrochloride *N*-Phenyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-amine

6-Bromo-N-(3-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(3-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-chlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(2-fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine

6-Bromo-N-(3,4-dichlorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine; and

6-Bromo-*N*-(4-fluorophenoxy)-2,3,4,9-tetrahydro-1*H*-carbazole.

26. (Currently amended) The A compound of claim 1 wherein the compound of formula (I) further comprises according to claim 1:

$$(R)p$$

$$(C)n$$

$$R^{7}$$

$$X - (R^{1})q$$

$$(I)$$

including salts, solvates and pharmaceutically functional derivatives wherein R⁶ is H, alkyl, -OR², -NR²R³, Ay, Het, -C(O)R², -CO₂R², -CONR²R³, -S(O)_mR², or oxo, where R² and R³ are as defined above; and

Attorney Docket no. PR60251USW Application no. 10/560,013

R⁷ is H or alkyl, provided that R⁶ and R⁷ are not both H; or a pharmaceutically acceptable salt or solvate thereof.

- 27. (Cancelled).
- 28. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. 37 (Cancelled).
- 38. (Currently amended) A method for the treatment or prophylaxis of oncogenic viruses, including adenoviruses, retroviruses, and a papovavirus family infection, including polyoma viruses infection and papilloma viruses infection comprising the administration administering to a subject in need thereof of a therapeutically effective amount of a compound according to any one of claim 1.
- 39. (Currently amended) A method for the treatment or prophylaxis of conditions or disorders due to HPV infection comprising the administration administering to a subject in need thereof of a therapeutically effective amount of a compound according to any one of claim 1.
- 40. (Original) The method of claim 39 wherein the condition or disorder is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.